| Year |
Citation |
Score |
| 2017 |
Sonawane P, Choi YA, Pandya H, Herpai DM, Fokt I, Priebe W, Debinski W. Novel Molecular Multilevel Targeted Antitumor Agents. Cancer Translational Medicine. 3: 69-79. PMID 28825042 DOI: 10.4103/ctm.ctm_12_17 |
0.88 |
|
| 2016 |
Gmeiner WH, Debinski W, Milligan C, Caudell D, Pardee TS. The applications of the novel polymeric fluoropyrimidine F10 in cancer treatment: current evidence. Future Oncology (London, England). PMID 27279153 DOI: 10.2217/fon-2016-0091 |
0.88 |
|
| 2016 |
Zhang J, Yu H, Qian X, Liu K, Tan H, Yang T, Wang M, Li KC, Chan MD, Debinski W, Paulsson A, Wang G, Zhou X. Pseudo progression identification of glioblastoma with dictionary learning. Computers in Biology and Medicine. 73: 94-101. PMID 27100835 DOI: 10.1016/j.compbiomed.2016.03.027 |
0.88 |
|
| 2015 |
Rodriguez A, Tatter SB, Debinski W. Neurosurgical Techniques for Disruption of the Blood-Brain Barrier for Glioblastoma Treatment. Pharmaceutics. 7: 175-87. PMID 26247958 DOI: 10.3390/pharmaceutics7030175 |
0.88 |
|
| 2015 |
Paw I, Carpenter RC, Watabe K, Debinski W, Lo HW. Mechanisms regulating glioma invasion. Cancer Letters. 362: 1-7. PMID 25796440 DOI: 10.1016/j.canlet.2015.03.015 |
0.88 |
|
| 2015 |
Holmes JA, Paulsson AK, Page BR, Miller LD, Liu W, Xu J, Hinson WH, Lesser GJ, Laxton AW, Tatter SB, Debinski W, Chan MD. Genomic predictors of patterns of progression in glioblastoma and possible influences on radiation field design Journal of Neuro-Oncology. DOI: 10.1007/s11060-015-1858-2 |
0.88 |
|
| 2015 |
Carpenter RL, Paw I, Zhu H, Sirkisoon S, Xing F, Watabe K, Debinski W, Lo HW. The gain-of-function GLI1 transcription factor TGLI1 enhances expression of VEGF-C and TEM7 to promote glioblastoma angiogenesis Oncotarget. 6: 22653-22665. |
0.88 |
|
| 2015 |
Johnson AG, Ruiz J, Hughes R, Brandi RP, Isom S, Lucas JT, McTyre ER, Houseknecht KW, Ayala-Peacock DN, Bourland DJ, Hinson WH, Laxton AW, Tatter SB, Debinski W, Watabe K, et al. Impact of systemic targeted agents on the clinical outcomes of patients with brain metastases Oncotarget. 6: 18945-18955. |
0.88 |
|
| 2014 |
Ferluga S, Debinski W. Ephs and Ephrins in malignant gliomas. Growth Factors (Chur, Switzerland). 32: 190-201. PMID 25418012 DOI: 10.3109/08977194.2014.985787 |
0.88 |
|
| 2014 |
Paulsson AK, Holmes JA, Peiffer AM, Miller LD, Liu W, Xu J, Hinson WH, Lesser GJ, Laxton AW, Tatter SB, Debinski W, Chan MD. Comparison of clinical outcomes and genomic characteristics of single focus and multifocal glioblastoma. Journal of Neuro-Oncology. 119: 429-35. PMID 24990827 DOI: 10.1007/s11060-014-1515-1 |
0.88 |
|
| 2014 |
Gmeiner WH, Lema-Tome C, Gibo D, Jennings-Gee J, Milligan C, Debinski W. Selective anti-tumor activity of the novel fluoropyrimidine polymer F10 towards G48a orthotopic GBM tumors. Journal of Neuro-Oncology. 116: 447-54. PMID 24346635 DOI: 10.1007/s11060-013-1321-1 |
0.88 |
|
| 2014 |
Rossmeisl JH, Garcia PA, Daniel GB, Bourland JD, Debinski W, Dervisis N, Klahn S. Invited review--neuroimaging response assessment criteria for brain tumors in veterinary patients. Veterinary Radiology & Ultrasound : the Official Journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association. 55: 115-32. PMID 24219161 DOI: 10.1111/vru.12118 |
0.88 |
|
| 2014 |
Paulsson AK, McMullen KP, Peiffer AM, Hinson WH, Kearns WT, Johnson AJ, Lesser GJ, Ellis TL, Tatter SB, Debinski W, Shaw EG, Chan MD. Limited margins using modern radiotherapy techniques does not increase marginal failure rate of glioblastoma. American Journal of Clinical Oncology. 37: 177-81. PMID 23211224 DOI: 10.1097/COC.0b013e318271ae03 |
0.88 |
|
| 2013 |
Baiz D, Hassan S, Choi YA, Flores A, Karpova Y, Yancey D, Pullikuth A, Sui G, Sadelain M, Debinski W, Kulik G. Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer. Neoplasia (New York, N.Y.). 15: 1172-83. PMID 24204196 DOI: 10.1593/neo.13986 |
0.88 |
|
| 2013 |
Debinski W, Dickinson P, Rossmeisl JH, Robertson J, Gibo DM. New agents for targeting of IL-13RA2 expressed in primary human and canine brain tumors. Plos One. 8: e77719. PMID 24147065 DOI: 10.1371/journal.pone.0077719 |
0.88 |
|
| 2013 |
Ferluga S, Hantgan R, Goldgur Y, Himanen JP, Nikolov DB, Debinski W. Biological and structural characterization of glycosylation on ephrin-A1, a preferred ligand for EphA2 receptor tyrosine kinase. The Journal of Biological Chemistry. 288: 18448-57. PMID 23661698 DOI: 10.1074/jbc.M113.464008 |
0.88 |
|
| 2013 |
Debinski W. Cytokine-directed recombinant cytotoxins for glioma treatment Gliomas: Symptoms, Diagnosis and Treatment Options. 357-369. |
0.88 |
|
| 2012 |
Nguyen V, Conyers JM, Zhu D, Gibo DM, Hantgan RR, Larson SM, Debinski W, Mintz A. A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker. Neuro-Oncology. 14: 1239-53. PMID 22952195 DOI: 10.1093/neuonc/nos211 |
0.88 |
|
| 2012 |
Beauchamp A, Lively MO, Mintz A, Gibo D, Wykosky J, Debinski W. EphrinA1 is released in three forms from cancer cells by matrix metalloproteases. Molecular and Cellular Biology. 32: 3253-64. PMID 22688511 DOI: 10.1128/MCB.06791-11 |
0.88 |
|
| 2012 |
Pandya H, Debinski W. Toward intracellular targeted delivery of cancer therapeutics: progress and clinical outlook for brain tumor therapy. Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. 26: 235-44. PMID 22671766 DOI: 10.2165/11631600-000000000-00000 |
0.88 |
|
| 2012 |
Lema Tomé CM, Palma E, Ferluga S, Lowther WT, Hantgan R, Wykosky J, Debinski W. Structural and functional characterization of monomeric EphrinA1 binding site to EphA2 receptor. The Journal of Biological Chemistry. 287: 14012-22. PMID 22362770 DOI: 10.1074/jbc.M111.311670 |
0.88 |
|
| 2012 |
Beauchamp A, Debinski W. Ephs and ephrins in cancer: ephrin-A1 signalling. Seminars in Cell & Developmental Biology. 23: 109-15. PMID 22040911 DOI: 10.1016/j.semcdb.2011.10.019 |
0.88 |
|
| 2012 |
Pandya H, Gibo DM, Garg S, Kridel S, Debinski W. An interleukin 13 receptor α 2-specific peptide homes to human Glioblastoma multiforme xenografts. Neuro-Oncology. 14: 6-18. PMID 21946118 DOI: 10.1093/neuonc/nor141 |
0.88 |
|
| 2011 |
Nguyen V, Conyers JM, Zhu D, Gibo DM, Dorsey JF, Debinski W, Mintz A. IL-13Rα2-Targeted Therapy Escapees: Biologic and Therapeutic Implications. Translational Oncology. 4: 390-400. PMID 22191003 DOI: 10.1593/tlo.11175 |
0.88 |
|
| 2011 |
Debinski W, Gibo DM. Fos-related antigen 1 (Fra-1) pairing with and transactivation of JunB in GBM cells. Cancer Biology & Therapy. 11: 254-62. PMID 21088499 DOI: 10.4161/cbt.11.2.13953 |
0.88 |
|
| 2010 |
Debinski W, Tatter SB. Convection-enhanced delivery to achieve widespread distribution of viral vectors: Predicting clinical implementation. Current Opinion in Molecular Therapeutics. 12: 647-53. PMID 21154156 |
0.88 |
|
| 2010 |
Candolfi M, Xiong W, Yagiz K, Liu C, Muhammad AK, Puntel M, Foulad D, Zadmehr A, Ahlzadeh GE, Kroeger KM, Tesarfreund M, Lee S, Debinski W, Sareen D, Svendsen CN, et al. Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. Proceedings of the National Academy of Sciences of the United States of America. 107: 20021-6. PMID 21030678 DOI: 10.1073/pnas.1008261107 |
0.88 |
|
| 2010 |
Pandya H, Gibo DM, Debinski W. Molecular targeting of intracellular compartments specifically in cancer cells. Genes & Cancer. 1: 421-33. PMID 20740056 DOI: 10.1177/1947601910375274 |
0.88 |
|
| 2009 |
Debinski W, Tatter SB. Convection-enhanced delivery for the treatment of brain tumors. Expert Review of Neurotherapeutics. 9: 1519-27. PMID 19831841 DOI: 10.1586/ern.09.99 |
0.88 |
|
| 2009 |
Tanaka ML, Debinski W, Puri IK. Hybrid mathematical model of glioma progression. Cell Proliferation. 42: 637-46. PMID 19624684 DOI: 10.1111/j.1365-2184.2009.00631.x |
0.88 |
|
| 2009 |
Liu TF, Cai J, Gibo DM, Debinski W. Reoxygenation of hypoxic glioblastoma multiforme cells potentiates the killing effect of an interleukin-13-based cytotoxin. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 160-8. PMID 19118043 DOI: 10.1158/1078-0432.CCR-08-2151 |
0.88 |
|
| 2008 |
Chen J, Zhuang G, Frieden L, Debinski W. Eph receptors and Ephrins in cancer: common themes and controversies. Cancer Research. 68: 10031-3. PMID 19074866 DOI: 10.1158/0008-5472.CAN-08-3010 |
0.88 |
|
| 2008 |
Wykosky J, Debinski W. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Molecular Cancer Research : McR. 6: 1795-806. PMID 19074825 DOI: 10.1158/1541-7786.MCR-08-0244 |
0.88 |
|
| 2008 |
Mintz A, Gibo DM, Madhankumar AB, Cladel NM, Christensen ND, Debinski W. Protein- and DNA-based active immunotherapy targeting interleukin-13 receptor alpha2. Cancer Biotherapy & Radiopharmaceuticals. 23: 581-9. PMID 18976118 DOI: 10.1089/cbr.2008.0462 |
0.88 |
|
| 2008 |
Wykosky J, Palma E, Gibo DM, Ringler S, Turner CP, Debinski W. Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor Oncogene. 27: 7260-7273. PMID 18794797 DOI: 10.1038/onc.2008.328 |
0.88 |
|
| 2008 |
Debinski W. Drug cocktails for effective treatment of glioblastoma multiforme. Expert Review of Neurotherapeutics. 8: 515-7. PMID 18416653 DOI: 10.1586/14737175.8.4.515 |
0.88 |
|
| 2008 |
Wykosky J, Gibo DM, Stanton C, Debinski W. Interleukin-13 receptor alpha 2, EphA2, and Fos-related antigen 1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 199-208. PMID 18172271 DOI: 10.1158/1078-0432.CCR-07-1990 |
0.88 |
|
| 2008 |
Debinski W. Molecular targeting with recombinant cytotoxins for the treatment of brain tumors Drug Development Research. 69: 407-414. DOI: 10.1002/ddr.20272 |
0.88 |
|
| 2007 |
Wykosky J, Gibo DM, Debinski W. A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells. Molecular Cancer Therapeutics. 6: 3208-18. PMID 18089715 DOI: 10.1158/1535-7163.MCT-07-0200 |
0.88 |
|
| 2007 |
Schwartzbaum JA, Ahlbom A, Lönn S, Malmer B, Wigertz A, Auvinen A, Brookes AJ, Collatz Christensen H, Henriksson R, Johansen C, Salminen T, Schoemaker MJ, Swerdlow AJ, Debinski W, Feychting M. An international case-control study of interleukin-4Ralpha, interleukin-13, and cyclooxygenase-2 polymorphisms and glioblastoma risk. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 16: 2448-54. PMID 18006935 DOI: 10.1158/1055-9965.EPI-07-0480 |
0.88 |
|
| 2006 |
Debinski W. Naturally occurring, unmodified bacterial toxin for the treatment of glioblastoma multiforme? Cancer Biology & Therapy. 5: 1569-70. PMID 17204857 |
0.88 |
|
| 2006 |
Schwartzbaum J, Feychting M, Ahlbom A, Malmer B, Doss H, Debinski W. Polymorphisms associated with asthma are inversely related to glioblastoma multiforme [2] Cancer Research. 66: 2878-2879. DOI: 10.1158/0008-5472.CAN-05-3200 |
0.88 |
|
| 2005 |
Couture D, Wykosky J, Gibo DM, Debinski W. 866 EphA2 Receptor Represents a New Marker and Therapeutic Target in Pediatric Malignancies. Neurosurgery. 57: 418-419. PMID 28184793 DOI: 10.1093/neurosurgery/57.2.418c |
0.48 |
|
| 2005 |
Wykosky J, Gibo DM, Stanton C, Debinski W. EphA2 as a novel molecular marker and target in glioblastoma multiforme. Molecular Cancer Research : McR. 3: 541-51. PMID 16254188 DOI: 10.1158/1541-7786.MCR-05-0056 |
0.88 |
|
| 2005 |
Debinski W. Personalized, multivalent, and more affordable: the globalization of vaccines. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 5663-4. PMID 16115899 DOI: 10.1158/1078-0432.CCR-05-1101 |
0.88 |
|
| 2005 |
Schwartzbaum J, Ahlbom A, Malmer B, Lönn S, Brookes AJ, Doss H, Debinski W, Henriksson R, Feychting M. Polymorphisms associated with asthma are inversely related to glioblastoma multiforme. Cancer Research. 65: 6459-65. PMID 16024651 DOI: 10.1158/0008-5472.CAN-04-3728 |
0.88 |
|
| 2005 |
Debinski W, Gibo DM. Fos-related antigen 1 modulates malignant features of glioma cells. Molecular Cancer Research : McR. 3: 237-49. PMID 15831677 DOI: 10.1158/1541-7786.MCR-05-0004 |
0.88 |
|
| 2004 |
Madhankumar AB, Mintz A, Debinski W. Interleukin 13 mutants of enhanced avidity toward the glioma-associated receptor, IL13Ralpha2. Neoplasia (New York, N.Y.). 6: 15-22. PMID 15068667 |
0.88 |
|
| 2003 |
Mintz A, Gibo DM, Madhankumar AB, Debinski W. Molecular targeting with recombinant cytotoxins of interleukin-13 receptor alpha2-expressing glioma. Journal of Neuro-Oncology. 64: 117-23. PMID 12952292 DOI: 10.1023/A:1024918916984 |
0.88 |
|
| 2003 |
Debinski W, Gibo D, Mintz A. Epigenetics in high-grade astrocytomas: opportunities for prevention and detection of brain tumors. Annals of the New York Academy of Sciences. 983: 232-42. PMID 12724228 |
0.88 |
|
| 2002 |
Zhou G, Ye GJ, Debinski W, Roizman B. Engineered herpes simplex virus 1 is dependent on IL13Ralpha 2 receptor for cell entry and independent of glycoprotein D receptor interaction. Proceedings of the National Academy of Sciences of the United States of America. 99: 15124-9. PMID 12417744 DOI: 10.1073/pnas.232588699 |
0.88 |
|
| 2002 |
Debinski W. Local treatment of brain tumors with targeted chimera cytotoxic proteins. Cancer Investigation. 20: 801-9. PMID 12197239 DOI: 10.1081/CNV-120003545 |
0.88 |
|
| 2002 |
Mintz A, Gibo DM, Slagle-Webb B, Christensen ND, Debinski W. IL-13Ralpha2 is a glioma-restricted receptor for interleukin-13. Neoplasia (New York, N.Y.). 4: 388-99. PMID 12192597 DOI: 10.1038/sj.neo.7900234 |
0.88 |
|
| 2002 |
Madhankumar AB, Mintz A, Debinski W. Alanine-scanning mutagenesis of alpha-helix D segment of interleukin-13 reveals new functionally important residues of the cytokine. The Journal of Biological Chemistry. 277: 43194-205. PMID 12189139 DOI: 10.1074/jbc.M205047200 |
0.88 |
|
| 2001 |
Debinski W, Slagle-Webb B, Achen MG, Stacker SA, Tulchinsky E, Gillespie GY, Gibo DM. VEGF-D is an X-linked/AP-1 regulated putative onco-angiogen in human glioblastoma multiforme. Molecular Medicine (Cambridge, Mass.). 7: 598-608. PMID 11778649 |
0.88 |
|
| 2001 |
Debinski W, Joshi BH, Plautz GE, Puri RK. Interleukin-13 receptor α chain: A novel tumor-associated transmembrane protein in primary explants of human malignant gliomas (multiple letters) Cancer Research. 61: 5660-5662. PMID 11454721 |
0.88 |
|
| 2001 |
Nash KT, Thompson JP, Debinski W. Molecular targeting of malignant gliomas with novel multiply-mutated interleukin 13-based cytotoxins Critical Reviews in Oncology/Hematology. 39: 87-98. PMID 11418305 DOI: 10.1016/S1040-8428(01)00124-X |
0.88 |
|
| 2000 |
Debinski W, Slagle B, Gibo DM, Powers SK, Gillespie GY. Expression of a restrictive receptor for interleukin 13 is associated with glial transformation. Journal of Neuro-Oncology. 48: 103-11. PMID 11083073 DOI: 10.1023/A:1006446426611 |
0.88 |
|
| 2000 |
Debinski W, Gibo DM. Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer/testis antigen Molecular Medicine (Cambridge, Mass.). 6: 440-449. PMID 10952023 |
0.88 |
|
| 2000 |
Mintz A, Debinski W. Cancer genetics/epigenetics and the X chromosome: Possible new links for malignant glioma pathogenesis and immune-based therapies Critical Reviews in Oncogenesis. 11: 77-95. PMID 10795628 |
0.88 |
|
| 1999 |
Debinski W. Recombinant cytotoxins specific for cancer cells Annals of the New York Academy of Sciences. 886: 297-299. PMID 10667244 |
0.88 |
|
| 1999 |
Debinski W, Thompson JP. Retargeting interleukin 13 for radioimmunodetection and radioimmunotherapy of human high-grade gliomas Clinical Cancer Research. 5. PMID 10541355 |
0.88 |
|
| 1999 |
Thompson JP, Debinski W. Mutants of interleukin 13 with altered reactivity toward interleukin 13 receptors Journal of Biological Chemistry. 274: 29944-29950. PMID 10514477 DOI: 10.1074/jbc.274.42.29944 |
0.88 |
|
| 1999 |
Debinski W, Gibo DM, Slagle B, Powers SK, Gillespie GY. Receptor for interleukin 13 is abundantly and specifically over-expressed in patients with glioblastoma multiforme International Journal of Oncology. 15: 481-486. PMID 10427128 |
0.88 |
|
| 1999 |
Debinski W, Gibo DM, Hulet SW, Connor JR, Gillespie GY. Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas Clinical Cancer Research. 5: 985-990. PMID 10353730 |
0.88 |
|
| 1999 |
Kornmann M, Kleeff J, Debinski W, Korc M. Pancreatic cancer cells express interleukin-13 and -4 receptors, and their growth is inhibited by pseudomonas exotoxin coupled to interleukin-13 and -4 Anticancer Research. 19: 125-131. PMID 10226533 |
0.88 |
|
| 1999 |
Hulet SW, Hess EJ, Debinski W, Arosio P, Bruce K, Powers S, Connor JR. Characterization and distribution of ferritin binding sites in the adult mouse brain Journal of Neurochemistry. 72: 868-874. PMID 9930764 DOI: 10.1046/j.1471-4159.1999.720868.x |
0.88 |
|
| 1998 |
Debinski W. An immune regulatory cytokine receptor and glioblastoma multiforme: An unexpected link Critical Reviews in Oncogenesis. 9: 255-268. PMID 10201630 |
0.88 |
|
| 1998 |
Debinski W, Gibo DM, Obiri NI, Kealiher A, Puri RK. Novel anti-brain tumor cytotoxins specific for cancer cells Nature Biotechnology. 16: 449-453. PMID 9592393 DOI: 10.1038/nbt0598-449 |
0.88 |
|
| 1998 |
Debinski W, Gibo DM, Puri RK. Novel way to increase targeting specificity to a human gliblastoma- associated receptor for interleukin 13 International Journal of Cancer. 76: 547-551. PMID 9590132 DOI: 10.1002/(SICI)1097-0215(19980518)76:4<547::AID-IJC17>3.0.CO;2-4 |
0.88 |
|
| 1997 |
Husain SR, Obiri NI, Gill P, Zheng T, Pastan I, Debinski W, Puri RK. Receptor for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein Clinical Cancer Research. 3: 151-156. PMID 9815666 |
0.88 |
|
| 1997 |
Murata T, Obiri NI, Debinski W, Puri RK. Structure of IL-13 receptor: Analysis of subunit composition in cancer and immune cells Biochemical and Biophysical Research Communications. 238: 90-94. PMID 9299458 DOI: 10.1006/bbrc.1997.7248 |
0.88 |
|
| 1997 |
Maini A, Hillman G, Haas GP, Wang CY, Montecillo E, Hamzavi F, Edson Pontes J, Leland P, Pastan I, Debinski W, Puri RK. Interleukin-13 receptors on human prostate carcinoma cell lines represent a novel target for a chimeric protein composed of IL-13 and a mutated form of pseudomonas exotoxin Journal of Urology. 158: 948-953. PMID 9258124 DOI: 10.1016/S0022-5347(01)64369-6 |
0.88 |
|
| 1997 |
Obiri NI, Murata T, Debinski W, Puri RK. Modulation of interleukin (IL)-13 binding and signaling by the γ(c) chain of the IL-2 receptor Journal of Biological Chemistry. 272: 20251-20258. PMID 9242704 DOI: 10.1074/jbc.272.32.20251 |
0.88 |
|
| 1997 |
Olson DJ, Gibo DM, Saggers G, Debinski W, Kumar R. Reversion of uroepithelial cell tumorigenesis by the ectopic expression of human wnt-5a Cell Growth and Differentiation. 8: 417-423. PMID 9101087 |
0.88 |
|
| 1997 |
Obiri NI, Leland P, Murata T, Debinski W, Puri RK. The IL-13 Receptor Structure Differs on Various Cell Types and May Share More Than One Component with IL-4 Receptor Journal of Immunology. 158: 756-764. PMID 8992992 |
0.88 |
|
| 1996 |
Obiri NI, Husain SR, Debinski W, Puri RK. Interleukin 13 inhibits growth of human renal cell carcinoma cells ependently of the p140 interleukin 4 receptor chain Clinical Cancer Research. 2: 1743-1749. PMID 9816125 |
0.88 |
|
| 1996 |
Debinski W, Miner R, Leland P, Obiri NI, Puri RK. Receptor for interleukin (IL) 13 does not interact with IL4 but receptor for IL4 interacts with IL13 on human glioma cells Journal of Biological Chemistry. 271: 22428-22433. PMID 8798406 DOI: 10.1074/jbc.271.37.22428 |
0.88 |
|
| 1996 |
Puri RK, Leland P, Obiri NI, Husain SR, Kreitman RJ, Haas GP, Pastan I, Debinski W. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR) Blood. 87: 4333-4339. PMID 8639793 |
0.88 |
|
| 1995 |
Debinski W, Pastan I. Recombinant F(ab') C242-Pseudomonas Exotoxin, but not the Whole Antibody-based Immunotoxin, Causes Regression of a Human Colorectal Tumor Xenograft Clinical Cancer Research. 1: 1015-1022. PMID 9816074 |
0.88 |
|
| 1995 |
Debinski W, Obiri NI, Powers SK, Pastan I, Puri RK. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 1: 1253-8. PMID 9815919 |
0.88 |
|
| 1995 |
Obiri NI, Debinski W, Leonard WJ, Puri RK. Receptor for interleukin 13: Interaction with interleukin 4 by a mechanism that does not involve the common γ chain shared by receptors for interleukins 2, 4, 7, 9, and 15 Journal of Biological Chemistry. 270: 8797-8804. PMID 7721786 |
0.88 |
|
| 1995 |
Debinski W, Obiri NI, Pastan I, Puri RK. A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4 Journal of Biological Chemistry. 270: 16775-16780. PMID 7622490 DOI: 10.1074/jbc.270.28.16775 |
0.88 |
|
| 1994 |
Debinski W, Pastan I. An immunotoxin with increased activity and homogeneity produced by reducing the number of lysine residues in recombinant Pseudomonas exotoxin Bioconjugate Chemistry. 5: 40-46. PMID 8199233 |
0.88 |
|
| 1994 |
Puri RK, Debinski W, Obiri N, Kreitman R, Pastan I. Human Renal Cell Carcinoma Cells Are Sensitive to the Cytotoxic Effect of a Chimeric Protein Composed of Human Interleukin-4 and Pseudomonas Exotoxin Cellular Immunology. 154: 369-379. PMID 8131209 DOI: 10.1006/cimm.1994.1084 |
0.88 |
|
| 1994 |
Debinski W, Puri RK, Pastan I. Interleukin-4 receptors expressed on tumor cells may serve as a target for anticancer therapy using chimeric Pseudomonas exotoxin International Journal of Cancer. 58: 744-748. PMID 8077061 |
0.88 |
|
| 1993 |
Wang Qc, Pai LH, Debinski W, FitzGerald DJ, Pastan I. Polyethylene Glycol-modified Chimeric Toxin Composed of Transforming Growth Factor a and Pseudomonas Exotoxin Cancer Research. 53: 4588-4594. PMID 8402632 |
0.88 |
|
| 1993 |
Debinski W, Puri RK, Kreitman RJ, Pastan I. A wide range of human cancers express interleukin 4 (IL4) receptors that can be targeted with chimeric toxin composed of IL4 and Pseudomonas exotoxin Journal of Biological Chemistry. 268: 14065-14070. PMID 8314773 |
0.88 |
|
| 1992 |
Debinski W, Karlsson B, Lindholm L, Siegall CB, Willingham MC, FitzGerald D, Pastan I. Monoclonal antibody C242-pseudomonas exotoxin A: A specific and potent immunotoxin with antitumor activity on a human colon cancer xenograft in nude mice Journal of Clinical Investigation. 90: 405-411. PMID 1644913 |
0.88 |
|
| 1992 |
Debinski W, Pastan I. Monovalent Immunotoxin Containing Truncated Form of Pseudomonas Exotoxin as Potent Antitumor Agent Cancer Research. 52: 5379-5385. PMID 1394141 |
0.88 |
|
| 1991 |
Debinski W, Siegall CB, Fitzgerald D, Pastan I. Substitution of foreign protein sequences into a chimeric toxin composed of transforming growth factor α and Pseudomonas exotoxin Molecular and Cellular Biology. 11: 1751-1753. PMID 1671711 |
0.88 |
|
| Show low-probability matches. |